Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients

OBJECTIVE: To test efficacy, safety and tolerability of Umifenovir in non-severe COVID-19 adult patients. METHODS: We carried out randomized, double-blind, placebo-controlled, multicenter, phase III trials involving adult (18-75 years), non-severe COVID19 patients, randomized 1:1 on placebo or Umife...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramachandran, Ravishankar, Bhosale, Vivek, Reddy, Himanshu, Atam, Virendra, Faridi, MMA, Fatima, Jalees, Shukla, Vaibhav, Khan, Zaw A, Khan, Hana, Singh, Vikram, Negi, Mahendra Pal Singh, Srivastava, Mukesh, Srivastava, Ajay Kumar, Tripathi, Chandra Bhushan, Ghosh, Nayan, Majumdar, Nilanjana, Tripathi, Raj Kamal, Rath, Srikanta Kumar, Mishra, Prabhat Ranjan, Sharma, Sharad, Kundu, Tapas K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603331/
https://www.ncbi.nlm.nih.gov/pubmed/34801738
http://dx.doi.org/10.1016/j.ijid.2021.11.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603331/
https://www.ncbi.nlm.nih.gov/pubmed/34801738
http://dx.doi.org/10.1016/j.ijid.2021.11.025

Ejemplares similares